Veradermics (MANE) director receives 51,525-share option and converts preferred

Rhea-AI Filing Summary

Veradermics, Inc. director Jane M. Grant-Kels reported acquiring equity through an option grant and a preferred stock conversion. On February 3, 2026, she received a stock option for 51,525 shares of common stock at an exercise price of $17 per share, which will be fully vested and exercisable on February 3, 2027.

On February 5, 2026, 2,455 shares of Series A Convertible Preferred Stock automatically converted into 2,455 shares of common stock on a 10.067-for-1 basis, without additional payment, immediately before the closing of Veradermics’ initial public offering, leaving her with 2,455 common shares held directly.

Insider Trade Summary

2,455 shares exercised/converted

Mixed 3 txns

Insider Grant-Kels Jane M.

Role Director

Type	Security	Shares	Price	Value
Conversion	Series A Convertible Preferred Stock	2,455	$0.00	--
Conversion	Common Stock	2,455	$0.00	--
Grant/Award	Stock Option (Right to Buy)	51,525	$0.00	--

Holdings After Transaction: Series A Convertible Preferred Stock — 0 shares (Direct); Common Stock — 2,455 shares (Direct); Stock Option (Right to Buy) — 51,525 shares (Direct)

Footnotes (1)

1. On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grant-Kels Jane M.

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		C(1)		2,455	A	(1)	2,455	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	02/05/2026		C			2,455	(1)	(1)	Common Stock	2,455	(1)	0	D
Stock Option (Right to Buy)	$17	02/03/2026		A		51,525		(2)	02/03/2036	Common Stock	51,525	$0	51,525	D

Explanation of Responses:

1. On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

2. This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Veradermics (MANE) director Jane M. Grant-Kels report?

Jane M. Grant-Kels reported two transactions: an automatic conversion of 2,455 Series A Convertible Preferred shares into 2,455 common shares, and a grant of stock options for 51,525 common shares at a $17 exercise price, both held directly.

How many Veradermics (MANE) common shares did the preferred stock convert into?

The filing states that 2,455 shares of Series A Convertible Preferred Stock automatically converted into 2,455 shares of Veradermics common stock on February 5, 2026, using a 10.067-for-1 conversion ratio immediately before the company’s initial public offering closing.

What are the key terms of the Veradermics (MANE) stock option granted to Jane M. Grant-Kels?

The stock option gives Jane M. Grant-Kels the right to buy 51,525 Veradermics common shares at an exercise price of $17 per share. The option becomes fully vested and exercisable on February 3, 2027, one year after the vesting commencement date.

When will Jane M. Grant-Kels’ Veradermics (MANE) stock option become fully vested?

The option will be fully vested and exercisable on February 3, 2027. This date represents the first anniversary of the vesting commencement date, meaning all 51,525 underlying common shares become available to exercise at that time.

Did the Veradermics (MANE) preferred stock conversion require additional payment?

No, the filing explains that the Series A Convertible Preferred Stock converted into common stock without payment of further consideration. The conversion occurred automatically immediately prior to the closing of Veradermics’ initial public offering at a fixed 10.067-for-1 ratio.

How many Veradermics (MANE) common shares does Jane M. Grant-Kels directly own after these transactions?

After the reported transactions, Jane M. Grant-Kels directly owns 2,455 shares of Veradermics common stock. She also holds a stock option covering an additional 51,525 common shares, which will be fully exercisable on February 3, 2027.